Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

Remon Abu-Elyazeed, William Jennings, Randall Severance, Michael Noss, Adrian Caplanusi, Michael Povey, Ouzama Henry
  • Human Vaccines & Immunotherapeutics, June 2018, Taylor & Francis
  • DOI: 10.1080/21645515.2018.1489186
The author haven't yet claimed this publicationThe author haven't yet claimed this publication
Read Publication

In partnership with: